AVIR
Atea Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$467.68M
P/E Ratio
—
EPS
$-1.94
Beta
0.16
52W High
$6.45
52W Low
$2.46
50-Day MA
$4.97
200-Day MA
$3.73
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $192.18M |
| Gross Profit (TTM) | $-146.53M |
| EBITDA | $-178.98M |
| Operating Margin | 0.00% |
| Return on Equity | -44.30% |
| Return on Assets | -28.70% |
| Revenue/Share (TTM) | $2.31 |
| Book Value | $3.52 |
| Price-to-Book | 1.67 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 58.97 |
| EV/EBITDA | -260.47 |
| Quarterly Earnings Growth (YoY) | 264.10% |
| Quarterly Revenue Growth (YoY) | 295.20% |
| Shares Outstanding | $79.67M |
| Float | $59.45M |
| % Insiders | 13.36% |
| % Institutions | 76.60% |
Analyst Ratings
Consensus ($8.83 target)
2
Buy1
HoldData last updated: 4/7/2026